Diagnostic and Precision Medicine Advances Transforming the Biotech Landscape

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE provides insights on recent developments and innovations in genetic diagnostics and precision medicine. The service also provides clinical trial analysis for utomilumab.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health

Table of Contents

Diagnostic and Precision Medicine Advances Transforming the Biotech LandscapeRecent Advances in Diagnostics and Precision MedicineAdvancing Genetic Diagnostics for Hereditary DisordersUndergoing Precision Medicine Through Blockchain TechnologyEvaluating Yescarta™ and Utomilumab Combination for Lymphoma ManagementBi-Specific Antibody Therapeutics for Inflammatory and Autoimmune IndicationsClinical Trial Analysis and Industry InteractionsClinical Trial Analysis for UtomilumabIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.